Jan Walewski
Overview
Explore the profile of Jan Walewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
4350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ribrag V, Bron D, Rymkiewicz G, Hoelzer D, Jorgensen J, de Armas-Castellano A, et al.
Lancet Haematol
. 2025 Feb;
12(2):e138-e150.
PMID: 39909657
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and...
2.
Marzolini M, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, et al.
Br J Haematol
. 2024 Nov;
206(3):876-886.
PMID: 39604791
Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the...
3.
Jiang L, Dreyling M, Hermine O, Mansmann U, Walewski J, Ribrag V, et al.
Br J Haematol
. 2024 Oct;
206(1):159-166.
PMID: 39442921
During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional survival captures their future survival probability. We investigated conditional...
4.
Borowiec A, Ozdowska P, Rosinska M, Zebrowska A, Jagiello-Gruszfeld A, Jasek S, et al.
Cardiooncology
. 2024 Sep;
10(1):64.
PMID: 39342402
Background: The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. Current guidelines of the European Society of Cardiology (ESC) for cardio-oncology do not...
5.
Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, et al.
J Clin Oncol
. 2024 Aug;
42(34):4071-4083.
PMID: 39159403
Purpose: The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. Methods: The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can...
6.
Kulecka M, Czarnowski P, Balabas A, Turkot M, Kruczkowska-Tarantowicz K, Zeber-Lubecka N, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125593
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to...
7.
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, et al.
Pol Arch Intern Med
. 2024 May;
134(5).
PMID: 38747414
No abstract available.
8.
Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Przybylowicz-Chalecka A, Jamroziak K, et al.
Blood
. 2024 May;
144(9):955-963.
PMID: 38713888
Mass spectrometry (MS) can detect multiple myeloma-derived monoclonal proteins in the peripheral blood (PB) with high sensitivity, potentially serving as a PB assay for measurable residual disease (MRD). This study...
9.
Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, et al.
Lancet
. 2024 May;
403(10441):2293-2306.
PMID: 38705160
Background: Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to...
10.
Zinzani P, Trneny M, Ribrag V, Zilioli V, Walewski J, Haaber Christensen J, et al.
EClinicalMedicine
. 2023 Aug;
62:102131.
PMID: 37599908
Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT...